PharmaNet’s Infectious Disease team consists of dedicated professionals committed to anti-infective drug development. Team members include clinicians, project managers, clinical research associates, data analysts, biostatisticians, and medical writers. These professionals offer a broad range of therapeutic expertise in bacteriology, virology, mycology, and associated diseases and syndromes and have a proven record of success working with:
 |
All forms of regulated anti-infective and immunologic agents, including drugs, biologics, and devices |
 All commonly studied populations, including pediatric |
|
|
Populations with unique clinical issues, including HIV infection and other immunocompromises, stem cell transplantation, chronic hepatitis, multidrug resistance, sepsis/septic shock, and trauma |
Global Clinical Development Services
The Infectious Disease Division provides a comprehensive range of services, with the ability to reach patients and investigators throughout the Americas, Europe, and the Asia-Pacific region. Available services include:
| Project feasibility studies, including epidemiological assessment |
| Clinical/Regulatory strategic planning and protocol development |
| Study design using targeted package-insert specifications |
| Identification of optimal regions and patient populations |
Case Studies
1. Meeting Enrollment Goals in a Hepatitis C Virus (HCV) Study
2. Overcoming a Short Enrollment Period in a Seasonal-Flu Study
William M. Egan, PhD Vice President, PharmaNet Consulting Dr. Egan offers more than 30 years of industry experience, including 28 years at FDA. At FDA, Dr. Egan served in various director-level positions in the Office of Vaccines Research and Review for more than 10 years. In those positions, Dr. Egan had oversight responsibility for the vaccine regulatory process in the United States. Dr. Egan's research experience within FDA also includes 13 years as the Chief for OVRR’s Biophysics Laboratory. Dr. Egan is a member of numerous professional organizations, including the American Chemical Society and the International Society for Biologicals, where he serves on the Scientific Conferences Committee. |
Patricia A. Mosher Vice President, Infectious Disease Operations Ms. Mosher provides clinical oversight to the management of projects conducted within the Infectious Disease Division. She has been in the industry for more than 23 years and has experience in the management of global trials from Phase I-IV involving:
Her experience with these therapies involves the treatment of:
Prior to joining PharmaNet, Ms. Mosher was involved in studies that lead to the approval of itraconazole in the treatment of histoplasma and blastomycosis in pulmonary mycoses in HIV/AIDS patients, as well as all the dermatophyte infection trials with this compound. |
Jeff Smith Director, Infectious Disease Operations Mr. Smith has worked in the pharmaceutical industry for more than 10 years, managing domestic and global trials in Phases I–IV. His experience emphasizes both infectious diseases and pulmonology trials involving vaccines, quinolones, and long-acting beta agonists in managing indications including influenza, complicated skin infections, tuberculosis, community-acquired pneumonia, bronchitis, and chronic obstructive pulmonary disease. In his current role, Mr. Smith provides operational oversight to the management of infectious disease programs. Mr. Smith was trained as a registered nurse and holds a Masters Certificate in Project Management. |
504 Carnegie Center, Princeton, NJ 08540